CompanyGraph
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392 · SSE · China
ystwt.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.85B, above the global median of $1.15B
- FinancialsAltman Z-Score 10.84: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
32.36BCNY4.85B · vs all stocks (USD)
Revenue (TTM)
2.02BCNY303.32M · vs all stocks (USD)
Profit Margin
-18.90%vs Biotechnology peers
Beta
0.7420xvs all stocks
52-Week Change
-53.40%vs all stocks
Market Capitalization
32.36BCNY4.85B · vs all stocks (USD)
Enterprise Value
27.77BCNY4.16B · vs all stocks (USD)
Forward P/E
43.82xvs Biotechnology peers
Price to Sales (TTM)
15.61xvs Biotechnology peers
Price to Book (MRQ)
2.69xvs Biotechnology peers
Enterprise to Revenue
13.72xvs Biotechnology peers
Enterprise to EBITDA
-70.40xvs Biotechnology peers
Gross Margin
57.99%vs Biotechnology peers
Profit Margin
-18.90%vs Biotechnology peers
Operating Margin
-23.03%vs Biotechnology peers
Return on Assets (TTM)
-3.11%vs Biotechnology peers
Return on Equity (TTM)
-3.31%vs Biotechnology peers
Revenue (TTM)
2.02BCNY303.32M · vs all stocks (USD)
Revenue per Share (TTM)
1.59CNYUpdated Oct 23, 2026Quarterly Revenue Growth
18.60%vs Biotechnology peers
Gross Profit (TTM)
848.61MCNY127.18M · vs all stocks (USD)
EBITDA (TTM)
-394.50MCNY-59.12M · vs all stocks (USD)
Net Income (TTM)
-382.55MCNY-57.33M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.55%vs Biotechnology peers
Operating Cash Flow (TTM)
74.98MCNY11.24M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-302.17MCNY-45.29M · vs all stocks (USD)
5-Year Average Dividend Yield
0.19%vs all stocks
Payout Ratio
400.00%vs Biotechnology peers
Minority Interest (Equity)
168.46MCNYFY2025 · Dec 31, 2025Revenue
1.82BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
921.83MCNYFY2025 · Dec 31, 2025Gross Profit
897.14MCNYFY2025 · Dec 31, 2025Operating Income
-426.41MCNY-63.91M · vs all stocks (USD)
Pre-tax Income
-480.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
-66.92MCNYFY2025 · Dec 31, 2025Net Income
-413.96MCNYFY2025 · Dec 31, 2025EBIT
-474.43MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.30MCNYFY2025 · Dec 31, 2025Research & Development
560.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
211.22MCNYFY2025 · Dec 31, 2025Other Operating Expenses
21.48MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
32.90MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.46MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-413.96MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
15.70MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-114.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
-709.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.34BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-413.96MCNYFY2025 · Dec 31, 2025Other Non-cash Items
36.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
398.16MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-135.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-594.44MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.93BCNYFY2025 · Dec 31, 2025Sale of Investments
4.76BCNYFY2025 · Dec 31, 2025Other Investing Activity
2.79MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-759.01MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
343.56MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-319.01MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
-21.80MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
471.66KCNYFY2025 · Dec 31, 2025Shares Outstanding
1.26BSharesUpdated Oct 23, 2026Float Shares
268.87MSharesUpdated Oct 23, 2026% Held by Insiders
82.09%vs all stocks
% Held by Institutions
2.39%vs all stocks
Total Cash (MRQ)
4.30BCNY644.25M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.40CNYUpdated Oct 23, 2026Total Debt (MRQ)
323.32MCNY48.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0272xvs Biotechnology peers
Current Ratio (MRQ)
4.23xvs Biotechnology peers
Book Value per Share (MRQ)
9.28CNYUpdated Oct 23, 2026Total Assets
14.04BCNY2.10B · vs all stocks (USD)
Total Current Assets
7.53BCNYFY2025 · Dec 31, 2025Total Liabilities
2.01BCNYFY2025 · Dec 31, 2025Total Non-current Assets
6.52BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
208.75MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.80BCNYFY2025 · Dec 31, 2025Cash
2.42BCNYFY2025 · Dec 31, 2025Cash Equivalents
12.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.43BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.45BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.62BCNYFY2025 · Dec 31, 2025Inventory
702.08MCNYFY2025 · Dec 31, 2025Accounts Payable
415.94MCNYFY2025 · Dec 31, 2025Short-term Debt
210.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.75MCNYFY2025 · Dec 31, 2025Long-term Debt
144.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.26BCNYFY2025 · Dec 31, 2025Retained Earnings
6.83BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
12.03BCNY1.80B · vs all stocks (USD)
52-Week Low
24.31CNYUpdated Oct 23, 202652-Week High
58.66CNYUpdated Oct 23, 202652-Week Change
-53.40%vs all stocks
Beta
0.7420xvs all stocks
50-Day MA
27.40CNYUpdated Oct 23, 2026200-Day MA
34.36CNYUpdated Oct 23, 2026Avg 10-Day Volume
4.89MSharesUpdated Oct 23, 2026Avg 30-Day Volume
5.72MSharesUpdated Oct 23, 2026Diluted EPS (TTM)
-0.2900CNYUpdated Oct 23, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Diagnostic
Inverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
The price reads stretched low, and net income and gross profit have fallen four years.
Reads
Diagnostic
Declining With Price Stretched Below 1Y Mean
The price sits well below its yearly mean, with net income and assets falling four years.
Reads
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.19Receivables vs revenue divergence: 4.89
High gross margins eroded by operating costsNotable
Gross Margin: 0.58Profit Margin: -0.19
Financial Health
Altman Z-Score 10.84: safe zoneNotable
Altman Z-Score: 10.84
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.85B, above the global median of $1.15BNotable
Market cap (USD): 4,849,165,522.559Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Haemonetics Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Iovance Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Erasca, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nexity SA
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDeclining With Price Stretched Below 1Y MeanInverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
Qatar National Cement Company
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDeclining With Price Stretched Below 1Y MeanInverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
Gc Cell Corp.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDeclining With Price Stretched Below 1Y MeanInverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases